R&G PharmaStudies Co. Ltd. A (301333) — Financial Flexibility Index
R&G PharmaStudies Co. Ltd. A (301333) has a Financial Flexibility Index of 0.17x as of June 2022. Free cash flow of CN¥46.22 Million (operating CF CN¥40.98 Million minus capex CN¥5.24 Million) represents 0% of total liabilities (CN¥264.39 Million). Also explore 301333 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
R&G PharmaStudies Co. Ltd. A Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Check 301333 financial resilience to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year free cash flow to debt coverage for R&G PharmaStudies Co. Ltd. A. For the full company profile including market capitalisation, see R&G PharmaStudies Co. Ltd. A stock valuation.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.31x | CN¥133.48 Million | CN¥114.20 Million | CN¥423.89 Million | ▼ -9.9% |
| 2024 | 0.35x | CN¥174.74 Million | CN¥154.76 Million | CN¥500.09 Million | ▼ -47.5% |
| 2023 | 0.67x | CN¥212.44 Million | CN¥192.56 Million | CN¥319.17 Million | ▲ +27.3% |
| 2022 | 0.52x | CN¥151.29 Million | CN¥130.47 Million | CN¥289.35 Million | ▼ -18.0% |
| 2021 | 0.64x | CN¥152.86 Million | CN¥114.57 Million | CN¥239.66 Million | ▲ +82.8% |
| 2020 | 0.35x | CN¥69.58 Million | CN¥44.10 Million | CN¥199.38 Million | ▼ -46.9% |
| 2019 | 0.66x | CN¥129.48 Million | CN¥103.48 Million | CN¥197.12 Million | — |